Globus Medical, Inc.
GMED · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.39 | 0.06 | 0.18 | -2.13 |
| FCF Yield | 2.84% | 0.39% | 1.36% | 1.71% |
| EV / EBITDA | 54.24 | 40.69 | 58.74 | 76.14 |
| Quality | ||||
| ROIC | 2.44% | 1.80% | 1.63% | 1.34% |
| Gross Margin | 0.00% | 66.62% | 67.33% | 59.92% |
| Cash Conversion Ratio | 2.10 | 0.38 | 2.35 | 7.94 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.20% | 33.78% | 32.93% | 35.05% |
| Free Cash Flow Growth | 599.22% | -77.02% | -29.51% | 19.50% |
| Safety | ||||
| Net Debt / EBITDA | -1.84 | -0.56 | -2.25 | -1.70 |
| Interest Coverage | 94.41 | 0.00 | 0.00 | 73.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.32 | 0.29 | 0.40 |
| Cash Conversion Cycle | 72.45 | 327.55 | 352.94 | 278.74 |